Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 8/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12721154 | 1.00 | PREP (0.48) | PREPPSMB5PSEN1PSEN2APH1B | |
| SCHEMBL18589064 | 0.85 | PREP (0.41) | PREPPSMB5PSEN1PSEN2APH1B | |
| SCHEMBL15891771 | 0.79 | CXCR2 (0.53) | PREPPSMB5PSEN1PSEN2APH1B | |
| SCHEMBL5899514 | 0.78 | CXCR2 (0.42) | PREPPSMB5PSEN1PSEN2APH1B | |
| SCHEMBL5899540 | 0.78 | CXCR2 (0.42) | PREPPSMB5PSEN1PSEN2APH1B | |
| SCHEMBL15890142 | 0.77 | CXCR2 (0.49) | PREPPSMB5PSEN1PSEN2APH1B | |
| SCHEMBL15780083 | 0.77 | CXCR2 (0.51) | PREPPSMB5PSEN1PSEN2APH1B | |
| SCHEMBL23662476 | 0.77 | PSMB5 (0.46) | PREPPSMB5PSEN1PSEN2APH1B | |
| SCHEMBL6237447 | 0.77 | PREP (0.53) | PREPPSMB5PSEN1PSEN2APH1B | |
| SCHEMBL6237454 | 0.77 | PREP (0.53) | PREPPSMB5PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012155042-A2 | NOVEL BORATE DERIVATIVES AND THEIR APPLICATIONS | ANDERSON DEVELOPMENT COMPANY (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289733-A1 | NOVEL BORATE DERIVATIVES AND THEIR APPLICATIONS | ANDERSON DEVELOPMENT COMPANY (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289733-A1 | NOVEL BORATE DERIVATIVES AND THEIR APPLICATIONS | BRS3, BRSK1, CA4 | PREP 4254/4885PSMB5 4732/4885PSEN1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.